logo-loader
viewScancell Holdings PLC

Scancell Holdings has AvidiMab paper published in prestigious cancer journal

The paper describes how AvidiMab modifications improve an antibody’s potential therapeutic properties

Scancell Holdings PLC -

Scancell Holdings PLC (LON:SCLP) has had a manuscript about its AvidiMab technology published in Cancer Research, the peer-reviewed journal of the American Association of Cancer Research (AACR).

The paper describes how AvidiMab modifications enhance the interaction (avidity) between the antibody and its target antigen to improve the antibody’s potential therapeutic properties, said Scancell.

This same modification also has demonstrated that Scancell’s tumour-associated glycan (TaG) antibodies can directly kill tumour cells.

Scancell said it has used AvidiMab technology to increase the avidity of TaG antibodies being evaluated for the treatment of cancer.

They are also being developed as antibody-drug conjugates (ADC).

The global therapeutic monoclonal antibody market was estimated to be worth US$150bn in 2019 and is predicted to grow to US$300bn by 2025.

Professor Lindy Durrant, Scancell’s chief scientific officer and author of the paper, said: “We are pleased to have our work published in the prestigious, peer-reviewed journal, Cancer Research.

“Our AvidiMab technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions.

“This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy.”

Quick facts: Scancell Holdings PLC

Price: 7 GBX

LSE:SCLP
Market: LSE
Market Cap: £32.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Scancell Holdings CEO discusses new research programme into coronavirus vaccine

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway speaks to Proactive London's Andrew Scott after revealing it's begun a research programme to develop a vaccine for the coronavirus. The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to use the company’s...

on 24/4/20

2 min read